Literature DB >> 24602874

Vaccines against neosporosis: what can we learn from the past studies?

Thierry Monney1, Andrew Hemphill2.   

Abstract

Neospora caninum is an intracellular apicomplexan parasite, which is a leading cause of abortion in cattle; thus neosporosis represents an important veterinary health problem and is of high economic significance. The parasite can infect cattle via trans-placental transmission from an infected cow to its fetus (vertical transmission), or through the oral route via ingestion of food or water contaminated with oocysts that were previously shed with the feces of a canid definitive host (horizontal transmission). Although vaccination was considered a rational strategy to prevent bovine neosporosis, the only commercialized vaccine (Neoguard®) produced ambiguous results with relatively low efficacy, and was recently removed from the market. Therefore, there is a need to develop an efficient vaccine capable of preventing both, the horizontal transmission through infected food or water to a naïve animal as well as the vertical transmission from infected but clinically asymptomatic dams to the fetus. Different vaccine strategies have been investigated, including the use of live attenuated vaccines, killed parasite lysates, total antigens or antigen fractions from killed parasites, and subunit vaccines. The vast majority of experimental studies were performed in mice, and to a certain extent in gerbils, but there is also a large number of investigations that were conducted in cattle and sheep. However, it is difficult to directly compare these studies due to the high variability of the parameters employed. In this review, we will summarize the recent advances made in vaccine development against N. caninum in cattle and in mice and highlight the most important factors, which are likely to influence the degree of protection mediated by vaccination.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Antigen; Apicomplexa; Immune response; Neospora caninum; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24602874     DOI: 10.1016/j.exppara.2014.02.015

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  20 in total

Review 1.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

2.  Differential Gamma Interferon- and Tumor Necrosis Factor Alpha-Driven Cytokine Response Distinguishes Acute Infection of a Metatherian Host with Toxoplasma gondii and Neospora caninum.

Authors:  Shannon L Donahoe; David N Phalen; Bronwyn M McAllan; Denis O'Meally; Milton M McAllister; John Ellis; Jan Šlapeta
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

3.  Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Vreni Balmer; Dustin J Maly; Erkang Fan; Luis-Miguel Ortega-Mora; Kayode K Ojo; Wesley C Van Voorhis; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes-Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice.

Authors:  Dennis Imhof; William Robert Pownall; Carling Schlange; Camille Monney; Luis-Miguel Ortega-Mora; Kayode K Ojo; Wesley C Van Voorhis; Anna Oevermann; Andrew Hemphill
Journal:  Front Vet Sci       Date:  2022-06-27

5.  Towards the First Multiepitope Vaccine Candidate against Neospora caninum in Mouse Model: Immunoinformatic Standpoint.

Authors:  Morteza Shams; Bahman Maleki; Bahareh Kordi; Hamidreza Majidiani; Naser Nazari; Hamid Irannejad; Ali Asghari
Journal:  Biomed Res Int       Date:  2022-06-09       Impact factor: 3.246

6.  Protective Effect against Neosporosis Induced by Intranasal Immunization with Neospora caninum Membrane Antigens Plus Carbomer-Based Adjuvant.

Authors:  Alexandra Correia; Pedro Alves; Ricardo Fróis-Martins; Luzia Teixeira; Manuel Vilanova
Journal:  Vaccines (Basel)       Date:  2022-06-10

7.  In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.

Authors:  Pablo Winzer; Joachim Müller; Adriana Aguado-Martínez; Mahbubur Rahman; Vreni Balmer; Vera Manser; Luis Miguel Ortega-Mora; Kayode K Ojo; Erkang Fan; Dustin J Maly; Wesley C Van Voorhis; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

8.  Determination of B and T Cell Epitopes in Neospora caninum Immune Mapped Protein-1 (IMP-1): Implications in Vaccine Design against Neosporosis.

Authors:  Naser Nazari; Bahareh Kordi; Bahman Maleki; Morteza Shams; Esfandiar Azizi; Hamidreza Majidiani; Razi Naserifar
Journal:  Biomed Res Int       Date:  2022-04-07       Impact factor: 3.411

Review 9.  A review of neosporosis and pathologic findings of Neospora caninum infection in wildlife.

Authors:  Shannon L Donahoe; Scott A Lindsay; Mark Krockenberger; David Phalen; Jan Šlapeta
Journal:  Int J Parasitol Parasites Wildl       Date:  2015-04-24       Impact factor: 2.674

10.  Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice.

Authors:  Joachim Müller; Adriana Aguado-Martinez; Vera Manser; Vreni Balmer; Pablo Winzer; Dominic Ritler; Isabel Hostettler; David Arranz-Solís; Luis Ortega-Mora; Andrew Hemphill
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-02-13       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.